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Abstract
Background: Rift Valley fever virus (RVFV; Phlebovirus, Bunyaviridae) is a mosquito–borne, zoonotic pathogen. In
Senegal, RVFV was first isolated in 1974 from Aedes dalzieli (Theobald) and thereafter from Ae. fowleri (de Charmoy),
Ae. ochraceus Theobald, Ae. vexans (Meigen), Culex poicilipes (Theobald), Mansonia africana (Theobald) and Ma.
uniformis (Theobald). However, the vector competence of these local species has never been demonstrated making
hypothetical the transmission cycle proposed for West Africa based on serological data and mosquito isolates.
Methods: Aedes vexans and Cx. poicilipes, two common mosquito species most frequently associated with RVFV in
Senegal, and Cx. quinquefasciatus, the most common domestic species, were assessed after oral feeding with three RVFV
strains of the West and East/central African lineages. Fully engorged mosquitoes (420 Ae. vexans, 563 Cx. quinquefasciatus
and 380 Cx. poicilipes) were maintained at 27 ± 1 °C and 70–80 % relative humidity. The saliva, legs/wings and bodies
were tested individually for the RVFV genome using real-time RT-PCR at 5, 10, 15 and 20 days post exposure (dpe) to
estimate the infection, dissemination, and transmission rates. Genotypic characterisation of the 3 strains used were
performed to identify factors underlying the different patterns of transmission.
Results: The infection rates varied between 30.0–85.0 % for Ae. vexans, 3.3–27 % for Cx. quinquefasciatus and 8.3–46.7 %
for Cx. poicilipes, and the dissemination rates varied between 10.5–37 % for Ae. vexans, 9.5–28.6 % for Cx. quinquefasciatus
and 3.0–40.9 % for Cx. poicilipes. However only the East African lineage was transmitted, with transmission rates varying
between 13.3–33.3 % in Ae. vexans, 50 % in Cx. quinquefasciatus and 11.1 % in Cx. poicilipes. Culex mosquitoes were less
susceptible to infection than Ae. vexans. Compared to other strains, amino acid variation in the NSs M segment proteins
of the East African RVFV lineage human-derived strain SH172805, might explain the differences in transmission potential.
Conclusion: Our findings revealed that all the species tested were competent for RVFV with a significant more important
role of Ae. vexans compared to Culex species and a highest potential of the East African lineage to be transmitted.
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Background
Rift Valley fever virus (RVFV) is an emerging mosquito-
borne, zoonotic pathogen in the genus Phlebovirus of
the family Bunyaviridae. The virus, first isolated in 1930
in Kenya [1], is transmitted primarily through the bites
of infected mosquitoes [2–4]. The genome of the virus
consists of three negative-stranded RNA segments called
large (L), medium (M), and small (S). Other modes of
transmission include direct contact with the blood, or-
gans, foetus, tissues or excretions of infected animals
through exposure to aerosols. Rift Valley fever (RVF) in
animals is characterised by high rates of abortion in preg-
nant females and deaths of young ruminants. The vast
majority of human infections are asymptomatic, but
symptomatic infections can lead to severe haemorrhages,
meningoencephalitis, retinopathy and in some cases death
[5–8]. The disease has cumulatively caused hundreds of
thousands of human infections and the deaths of more
than 2000 humans and millions of domestic animals in
Kenya [9]. To date, no specific treatment against RVF is
available. For humans, the available vaccine is restricted to
the use for at-risk personnel only, as multiple inoculations
are required to achieve protective immunity [10]. Several
veterinary vaccine candidates were proposed (MP12,
Clone 13, and the Smithburn neurotropic strain), but
adverse effects were observed after vaccination [11–13].
Another candidate vaccine (R566) is still currently
under investigation [14]. Recently, the MP-12 virus
containing a deletion in the NSs gene proved promis-
ing as it prevented lethal disease when administered
to hamsters [15]. Nonetheless, this new generation of
genetically modified vaccines are not yet approved for
use in humans or animals.
The recent expansion of RVFV from Africa into Saudi
Arabia and Yemen in 2000, and the outbreaks recorded in
Africa, particularly those in Mauritania in 2003, 2010 and
2012 [16–19], in Senegal in 2012 and 2013 [20], in Kenya
[21, 22], and in Mayotte in 2008 [23], reflect the ongoing
emerging potential of the virus. The introduction and
spread of the virus into new areas were mainly linked
to the migration of infected animals [24], but the dis-
persal of infected vectors could not be ruled out. As
no specific treatment against the RVFV is available,
prevention is key, and control of epidemics centred on
vector control and the vaccination of cattle and popula-
tions at risk (i.e., veterinarians, slaughterhouse staff and
medical surveillance personnel, among others).
In Senegal, RVFV was first isolated in 1974 from the
mosquito Ae. dalzieli collected in Kedougou during a
Yellow Fever (YF) surveillance programme. Following the
first extensive RVFV outbreak in Mauritania in 1987, the
active surveillance programme implemented resulted in
the detection of several animal cases and also the isolation
of the virus from several mosquito species, including Ae.
fowleri, Ae. ochraceus, Ae. vexans, Cx. poicilipes, Ma..
uniformis and Ma. africana [25–27].
Based on isolates from mosquitoes and the sero-
epidemiological data gathered from animals, a transmission
cycle similar to that of East Africa was proposed for West
Africa. However, this transmission cycle is still hypothetical,
because specific entomological parameters such as vector
competence of the local species of mosquito for RVFV re-
main to be determined [28]. Furthermore, although ento-
mological surveillance provided essential information on
circulation of the virus and ecology of the vectors, this ap-
proach did not determine the effect of RVFV amplification
on human populations. Human cases of RVFV are still rare
in Senegal [29]. The data generated during a trans-sectional
study and following an epizootic event revealed a low sero-
prevalence of IgG in human populations that ranged from
14.02–22.3 % in 1989 in Yonoféré [30] and 6.12 % in
Barkédji in 1993 [29]. The seroprevalence was from 5–26 %
amongst children born after the 1987 epidemic, and 25.3 %
amongst adults [28, 29]. A low seroprevalence of IgG
against RVFV during an investigation of an epidemic was
also recorded in Diawara, northern Senegal (5.2 %), and in
the south of the country (≤3.1 %) in Kedougou, Tamba-
counda and Casamance [31–33]. Several factors could ex-
plain the difference in infection rates between animals and
humans, including the efficiency of transmission by the vec-
tor or ecological parameters of the vector.
The purpose of the present study was to investigate
the vector competence of Ae. vexans and Cx. poicilipes,
the two most common mosquito species in the Barkédji
area and the species most frequently associated with the
RVFV in Senegal, and that of Cx. quinquefasciatus, the
most common domestic species, for different strains and
lineages of the RVFV.
Methods
Mosquito species
The mosquito species Ae. vexans, Cx. poicilipes and Cx.
quinquefasciatus were collected in Barkédji (15°17′N,
14°53′W). Aedes vexans and Cx. quinquefasciatus were
chosen as target organisms due to their widespread
Afrotropical distribution and potential involvement in
the transmission cycle of RVFV in Senegal and neigh-
bouring countries [26, 28]. Aedes vexans is regularly
found naturally infected with RVFV in West Africa [25,
27, 34], has a worldwide distribution and is a biting nuis-
ance pest also in Europe and America. The wide distri-
bution of Ae. vexans is a major concern because of the
potential for RVFV to invade new geographic areas, as
occurred during the epidemic / epizootic in Saudi Arabia
[35, 36]. In West Africa, the abundance and the biology
of Ae. vexans, including the close interactions with ver-
tebrate hosts, highlight the potentially important role
that this species may play in the transmission of RVFV.
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Culex quinquefasciatus was selected because this spe-
cies is the member of the Cx. pipiens complex best
adapted to the tropical and sub-tropical regions. Culex
pipiens was implicated in the transmission of RVFV dur-
ing an outbreak in Egypt and on the Arabian Peninsula
[36, 37]. In tropical regions, Cx. quinquefasciatus is ubi-
quitous, colonizing domestic environments year-round
because of its association with artificial breeding sites.
This species is abundant, anthropophagic and a compe-
tent vector for arboviruses in some geographic locations,
making it a good candidate for the study of RVFV trans-
mission in urban settings.
Culex poicilipes was targeted in this study as it is con-
sidered as one of the main vectors of RVFV in West
Africa due to its abundance, bionomics and the number
of RVFV strains isolated from this species in Senegal and
Mauritania [26, 38]. In our previous studies, the domin-
ance in abundance regularly switched between Cx. poicilipes
and Ae. vexans in Barkédji [39, 40]. Feeding preference stud-
ies indicated that Cx. poicilipes was mainly attracted to bo-
vines and sheep, adding further indication as to its vectorial
potential [41].
Virus strains and preparation of the stocks
The three RVFV strains used in this study were isolated
from goats (AnD133719), mosquitoes (ArD141967)
(both West African lineages), and humans (SH172805,
East/central African lineage) in Mauritania in the years
1998, 2000, and 2003, respectively (Table 1). The viral
stock of each strain used to infect mosquitoes was pre-
pared from the brains of suckling mice inoculated intra-
cerebrally with 20 μl of the virus. Brains were triturated
in Leibovitz-15 (L-15) medium (GibcoBRL, Grand
Island, NY, USA) containing penicillin and streptomycin
(Sigma, GmBh, Germany) and 10 % FBS (Gibco BRL,
Grand Island, NY, USA). After centrifugation, the sus-
pension was aliquoted, and stored at −80 °C.
Experimental infection procedure
Three to five day-old F1 generation female mosquitoes
were starved for 48 h and then exposed for 1 h to an in-
fectious blood meal, using the previously described arti-
ficial feeding method using a mouse skin membrane
[42]. The infectious blood meal contained at equal vol-
ume, washed rabbit erythrocytes, foetal bovine serum
(FBS) and the viral suspension of one of the three
natural RVFV strains described above. As a phagostimu-
lant, adenosine triphosphate (ATP) was added to a final
concentration of 0.005 M. For each infection experi-
ment, a sample of the virus-blood suspension was col-
lected at the end of the mosquito feeding for virus
titration. At the end of feeding, the mosquitoes were
cold anaesthetised, and fully engorged specimens were
selected and subsequently maintained in an incubator at
27 °C, a relative humidity of 70–80 % and 10 % sucrose
for food. Between 25 and 40 individuals were randomly
selected for each batch at 5 days post exposure (dpe), 25
to 50 at 10 dpe, 36 to 100 at 15 dpe, and 6 to 66 at 20
dpe (Fig. 3). Mosquitoes were again cold anaesthetised,
and the legs and wings removed and put together in a
tube. Each of these mosquitoes was then forced to
salivate individually into a capillary tube containing FBS.
After 15–20 min of salivation, the mosquitoes were
removed, and the FBS-saliva mix was added into a vial
containing 500 μl of L-15 medium.
Virus detection in mosquitoes
The mosquito bodies, legs/wings and collected saliva
were stored separately at −80 °C until virus detection
was attempted by real-time RT-PCR. All mosquito bod-
ies as well as the legs/wings of infected bodies and saliva
of infected legs/wings were tested for presence of virus.
The samples were homogenised in 500 μl of L-15 cell
culture medium containing 20 % FBS and were then
centrifuged for 20 min at 10,000 rpm at 4 °C. For real-
time PCR, 100 μl of supernatant was used for RNA
extraction using the QIAamp Viral RNA Extraction Kit
(QIAgen, Heiden, Germany), according to the manufac-
turer’s protocol. The RNA was amplified using ABI
Prism 7000 SDS Real-Time apparatus (Applied BioSys-
tems, Foster City, CA, USA) with the QuantiTect kit
(QIAgen).
The RT-PCR was performed in a 25 μl reaction vol-
ume containing 5 μl of extracted RNA (Triplicate), 2x
QuantiTect Probe, RT-Master Mix, 10 μM of each pri-
mer and 200 nM of the probe. The specific primers and
probe sequences for RVFV used were first described in
Weidman et al. [43]. The thermal profile was as follows:
a single cycle of reverse transcription for 10 min at 50 °
C, 15 min at 95 °C for reverse transcriptase inactivation
and DNA polymerase activation, and then 40 amplifica-
tion cycles of 15 s at 95 °C and of 1 min at 60 °C
Table 1 RVFV strains used in this study, and titre of virus in the infectious blood meal after exposure
Virus strain Host Origin Geographic
Origin
Year of
isolation
Passage
history
Lineage Virus titer post exposure (PFU/ml)
Ae. vexans Cx. quinquefasciatus Cx. poicilipes
SHM172805 Human Mauritania 2003 3 East/Central Africa 4.5 × 106 1.5 × 106 9.7 × 108
ArD141967 Cx. poicilipes Mauritania 2000 4 West Africa 5.5 × 106 5.5 × 108 1.1 × 107
AnD133719 Goat Mauritania 1998 7 West Africa 9.5 × 106 1.7 × 106 3 × 106
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(annealing-extension step). Fluorescence was analysed at
the end of the amplifications.
Viral RNA extraction, RT-PCR and sequencing
The RNA were extracted from the three viral stocks
(AnD133719, SHM172805 and ArD141967) and were
used as templates for RT-PCR. Specific primers (Table 2),
the M-MLV system (Invitrogen, Carlsbad, CA, USA),
and the Go-Taq PCR Kit (Promega, Madison, WI, USA)
were used for cDNA synthesis and amplification, accord-
ing to the manufacturer’s instructions. All primers used
to amplify the S and M segments were designed according
to RVFV sequences available in GenBank. Accession num-
bers of all RVFV sequences used to design the primers are
presented in Additional file 1: Table S1. The PCR products
of the expected sizes were purified directly from the agar-
ose gel using a QIAgen Gel extraction kit and sequenced
by Cogenics (Beckman Coulter Genomics, Essex, United
Kingdom). Sequencing was performed in both directions,
using the original reverse and forward primers as for the
amplification.
Data analysis
Detection of RVFV in the mosquito bodies without the
subsequent detection of the infection in the legs/wings
was considered a non- disseminated infection, which
was limited to the midgut. Conversely, detection of the
virus in both the mosquito legs/wings and saliva indi-
cated a disseminated infection from the midgut into the
mosquito haemocoel and the potential for transmission,
respectively. The infection rate (number of infected mos-
quito bodies per 100 mosquitoes tested), the dissemin-
ation rate (number of mosquitoes with infected legs/wing
per 100 mosquitoes infected) and the transmission poten-
tial (number of mosquitoes with infected saliva per 100
mosquitoes with infected legs/wings) were calculated and
compared for each mosquito species, according to dpe
and the viral strains. Fisher’s exact tests were performed
to compare the rates of infection, dissemination and
transmission using the R statistical software package
(R Foundation for Statistical Computing, Vienna, Austria).
Differences were considered statistically significant at
P < 0.05.
Nucleotides sequences from Beckman Coulters were
analysed and assembled with GeneStudio, version 2.2.0.0
(http://genestudio.com/). The amino acid sequences were
then aligned using MEGA 5.05 software [44] to identify
variable motifs between the human (SHM172805) and
other strains that could explain the different patterns in
the mosquito species tested.
Results
The sequences of the S and M segments of the coding re-
gion obtained for the three strains of virus were aligned
using MEGA. Based on these alignments, variation in
amino acids were observed in the NSs, NSm, Gc and Gn
proteins of the human strain (SHM172805) compared to
the two other strains (Figs. 1 and 2). This variability
occurred primarily among amino acids of the same type
(I/V/M and R/K) but also between amino acids of differ-
ent types, acid/polar, polar/apolar, and aliphatic/aromatic
(D/N, V/T, L/F respectively). The N-linked glycosylation
sites of the envelope proteins were all conserved.
A total of 420 Ae. vexans, 563 Cx. quinquefasciatus
and 380 Cx. poicilipes were tested for RVFV compe-
tence. All three virus strains (with virus titers ranging
from 1.5× 106 pfu/ml to 9.7 × 108 pfu/ml) infected the
three species of mosquito and were disseminated, but
only the East African lineage RVFV was capable of being
transmitted by all three species. Infection rates varied
between 30 and 85 % for Ae. vexans, 3.3–27 % for Cx.
quinquefasciatus and 8.3–46.7 % for Cx. poicilipes. For
each mosquito-virus combination, the infection rates
were comparable at each dpe, as well between the differ-
ent dpe. However, significant variation was detected
when comparing the infection rates by the different virus
strains at different dpe (Fig. 3 and Additional file 2:
Table S2).
The infection rates of Ae. vexans with the ArD141967
strain were significantly lower than those with the
SH172805 strain (P ≤ 0.04). The same trend was ob-
served between the ArD141967 and the AnD133719
strains (P ≤ 0.03), except at 20 dpe (P = 0.3). However, no
significant difference was recorded between the infection
rates of AnD133719 and SH172805 (P ≥ 0.25). With Cx.
quinquefasciatus, the infection rates were similar be-
tween SH172805 and ArD141967 strains. AnD133719
was the only strain that exhibited infection rates sig-
nificantly lower than those of the SH172805 strain
(P = 0.03) and the ArD141967 strain (P = 0.004).
For Cx. poicilipes, no significant differences were ob-
served irrespective of dpe (P > 0.05), except at 10 and 15
dpe with the ArD141967 strain (P = 0.021). Comparison
Table 2 List of primers used
Nom Segment Position Sequence Tm
NSng S 31–48 TATCATGGATTACTTTCC 48
NSca S 841–824 CCTTAACCTCTAATCAAC 50
M1F M 3–22 ACAAAGACCGGTGCAACTTC 53.9
M1R M 1120–1140 CCAYGCAAAGGGTATGCAAT 53.2
M2F M 1035–1054 TGAGGACTCTGAATTRCACCT 48.7
M2R M 2395–2415 TCCAGAGAGTTGAGCCTTGC 53.3
MRV1a M 3050–3068 CAAATGACTACCAGTCAGC 44.6
MRV2g M 2262–2292 GGTGGAAGGACTCTGCGA 52.5
M3F M 2979–2998 CAGTCCTCAGTGAGCYCATA 46.1
M3R M 3763–3782 TCTCGGTTCTGGRGTGTGAA 52.5
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NSs AEF79995.1| South Africa 1974 V I S I I V R A V V I E E
NSs ACE78446.1| Kenya 2007 A . N . . . . . I . M . G
NSs YP 003848706.1| Egypt 1977 A . N . . A K V I I M . .
NSs ACA14356.1| Mauritania 1988 A . N . V . K . I . M D G
..MII.K...NVA917331DnAsSN
.DMII.K...N.A769141DrAsSN
NS SHM172805 A N V K I G
75     111    133    141     151    167     202    217   239    242    250    251     253
s . . . . . . .
Fig. 1 Alignment of S segment. NSs proteins were aligned and variable amino acids were shown with their positions refer to the genome
sequence of South Africa 1974 (Accession number: AEF79995.1). Human strain SHM172805 (East/Central African lineage) is in bold. Dots:
conserved amino acids. Rectangles: variables amino acids in the human strain sequence compared to ArD141967 and AnD133719 (West
African lineage)
NSm YP003848705.1 Egypt 1977 I D G R
NSm ACE78395.1 Kenya 2007 V N . .
NSm AFD98306.1 South Africa 2009 . . . .
NSm ACE78394.1 Kenya 2007 V N . .
....917331DnAmSN
.S..769141DrAmSN
NSm SHM172805 V N . .
60      95     105    120
Gn YP003848705.1 Egypt 1977 L V M D I K R D V I I R K R K I V
Gn ACE78395.1 Kenya 2007 Q . . . . . . G I T V . . . . V A
Gn AFD98306.1 South Africa 2009 Q . I . . . . G . V . K R K . V A
232    373     385   386   442     453    494     566    589    595    602     605    608     615    616    631     659
A
B
Gn ACE78394.1 Kenya 2007 Q . . . . . . G . . . . . . . V .
AV.K.K.V.G.R.G..Q917331DnAnG
AV...K.V.GQ.....Q769141DrAnG
Gn SHM172805 Q I . . T . . G . T V . . . R V A
Gc YP003848705.1 Egypt 1977 V Y E I R F T T I S L
Gc ACE78395.1 Kenya 2007 . . . . . . . . V T .
Gc AFD98306.1 South Africa 2009 I . . . . . . . . T .
Gc ACE78394.1 Kenya 2007 . . . . . . . . . T .
FT.IS..MDH.917331DnAcG
FT...L.....769141DrAcG
Gc SHM172805 . . . . . . . . . T .
685      687   739  747    848   850   860  872   954  1059  1185
C
Fig. 2 Alignment of M segment. M proteins were aligned and variable amino acids in NSm, Gn and Gc proteins were shown with their positions
refer to the genome sequence of Egypt 1977 (Accession number: YP003848705.1). Human strain SHM172805 is in bold. Dots: conserved amino
acids. Rectangles: variables amino acids in the human strain sequence compared to ArD141967 and AnD133719
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among the viral strains revealed that at 10 dpe, the
SH172805 strain was more infectious than the
ArD141967 strain (P = 0.016), and at 15 dpe, the infection
rate of the AnD133719 strain was significantly lower than
both the ArD141967 (P = 0.00049) and SH172805 strain
(P = 0.0002).
Based on a pairwise analysis of infection rates between
the species, Ae. vexans was generally more susceptible to
infection than Cx. quinquefasciatus. The unique excep-
tion was the infection obtained with the ArD141967
strain at 15 dpe, when the infection rate of Ae. vexans was
significantly higher than that of Cx. quinquefasciatus
(P = 0.001). Indeed using the same strain of virus, a com-
parable rate of infection was found for Ae. vexans and Cx.
quinquefasciatus at 5, 10, and 20 dpe (P ≥ 0.3).
Independent of the virus strain used, dissemination
rates were relatively low for the three species of mosqui-
toes ranging from 10.5–37 % in Ae. vexans, from 9.5–
28.6 % in Cx. quinquefasciatus and from 3–40.9 % in
Cx. poicilipes. Dissemination was recorded relatively
quickly in Ae. vexans at 5 dpe for the SH172805 strain
but was delayed to 10, and 15 dpe, for the ArD141967
and AnD133719 strains, respectively. With the exception
of the significant difference observed at 15 dpe between
the AnD133719 and SH172805 strains (P = 0.001), the
dissemination rates were comparable for all virus strains
and incubation periods (P ≥ 0.07). In Cx. quinquefasciatus,
the dissemination rates remain similar irrespective of the
dpe (P ≥ 0.1). This species did not disseminate the
ArD141967 strain, despite the high viral titres of 5.5108
PFU/ml detected in the blood meal post-feeding. The
observation was similar for Cx. poicilipes, which did not
disseminate the animal strain (AnD133719).
For all mosquito species tested, only the SH172805 strain
was transmitted (i.e. present in saliva) from 10 dpe and
thereafter for Ae. vexans, 15 dpe for Cx. poicilipes and only
after 20 dpe for Cx. quinquefasciatus. The transmission
rates ranged from 13.–33.3 % for Ae. vexans and was
11.1 % for Cx. poicilipes and 50 % for Cx. quinquefasciatus,
but the differences between the three species and the dpe
were not significant (P ≥ 0.05).
Discussion
Our study showed that the three mosquito species were
susceptible to infection by the different RVFV strains
with Ae. vexans mosquitoes being more susceptible than
Cx. poicilipes or Cx. quinquefasciatus. The highest infec-
tion rates were obtained with Ae. vexans, which was also
the only species that disseminated all the virus strains
and transmitted the SH172805 strains at different dpe.
Despite a lower viral titre (≈ 106 PFU/ml) in the blood
meal post-feeding, the rates of infection, dissemination
and transmission rates obtained were as high as those
obtained in US populations of Ae. vexans that were
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Fig. 3 RVFV infection, dissemination and transmission rates throughout incubation periods as indicated for Ae. vexans, Cx. quinquefasciatus and Cx.
poicilipes that were orally exposed to infectious blood meal containing 106-108 PFU/ml virus suspension with RVFV strains SH72805, ArD14196 or
AnD133719. N: number of specimens tested. dpe: day post exposure
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exposed to a viraemic animal that exceeded or was equal
to 108.5 PFU/ml [45]. The rates of infection, dissemin-
ation and transmission were 47.9–95.4 %, 10.3–60.8 %
and 25–100 %, respectively. However, our results dif-
fered from those of other studies [46] that reported ab-
sence of competence after exposure to viral titres that
ranged from 107.9–109 PFU/ml and led to an infection
rate of only 15 % without dissemination or transmission.
Geographical diversity in the competence of Ae. vexans
has already been observed in populations from different
localities in the USA. Populations from Louisiana and
Florida exhibited 27 % transmission rates, whereas the
rate of transmission in colonies from Colorado and Cali-
fornia was only 1 % [47]. Indeed, the Ae. vexans complex
includes three subspecies: Ae. vexans vexans (Meigen,
1830) found in Europe, Ae. vexans nipponii (Theobald,
1907) from eastern Asia, and Ae. vexans arabiensis
(Patton, 1905) is the only representative in Africa. Be-
cause this study focused on only one strain of each mos-
quito species and vector competence of mosquito
populations can vary spatially, our results may not apply
to population from other regions of West Africa. Further
studies are needed to evaluate the vector competence of
other populations of these species for RVFV.
The low infection rates among the two Culex species
observed in our study are consistent with previous results
of Cx. quinquefasciatus from South Africa, Australia and
the south-eastern United States [45, 47–50], with a max-
imum infection rate of 26 %, without dissemination and
transmission. The low transmission rate (11.1 %) found
here for Cx. poicilipes is similar to the results of a previous
South African study at 15 dpe [51]. This transmission rate
could become higher with longer incubation periods, as it
was suggested that the South African population of Cx.
poicilipes reached 80 % transmission after 30 days of
extrinsic incubation.
Only the RVFV strain belonging to the East African
lineage (SH172805) was transmitted. These observed
variations were not caused by differences in viral titres
because no significant correlation was observed between
viral titres and infection rates. Contrary to our findings,
Turell et al. [47] found that mosquito infection and dis-
semination rates were higher when mosquitoes were ex-
posed to higher viral doses. This discordance could be
explained by differences in mosquito strains and the ex-
perimental protocol.
The genetic variability of the virus strains used in our
experiment could explain the differences in patterns of
infection and transmission. The results of the sequence
analysis of a portion of the genome at the L, M and S
segments provided some support for this hypothesis. In-
deed, in addition to classification into the East African
lineage, the alignment of partial segments showed a
number of differences between the M and S segments of
the SH172805 strain to those of the other West African
strains. Amino acid changes were detected in the NSs,
NSm, Gc and Gn proteins of the human East African
strain compared with those of the West African strains.
Notably, the M segment proteins are essential and ne-
cessary for virus spread. Indeed the Gn and Gc proteins
are implicated in the RVFV entry during infection, al-
though the cell receptor remains unknown [52, 53]. The
M segment proteins also play important roles in the as-
sembly of the Golgi and the budding of viral particles
[54]. It has been shown that the NSm protein has an
anti-apoptotic function and a negative effect on virus de-
velopment in the cell [55–57]. Additionally, NSm has
been described to play a functional role in influencing
vector competence for RVFV at the level of the midgut
barrier [58]. The NSs protein acts on the antiviral re-
sponse of mammalian cells by direct or indirect inhib-
ition of transcription factor [59, 60]. Alone or combined,
these two proteins (NSs and NSm) affect vector compe-
tence of some species by reducing the rate of infection
or the potential to transmit the virus [61]. Therefore, the
single amino acid mutations observed in all these pro-
teins could influence the viral replication and lead to dif-
ferent patterns of transmission. A single amino acid
mutation can indeed enhance transmission in a mos-
quito vector. In chikungunya virus, a single mutation
(A226V) in the E1 glycoprotein enhanced viral transmis-
sion by Ae. albopictus [62, 63]. Further studies are re-
quired to assess the effects of these amino acid
differences between RVFV strains. Studies with reassor-
tant viruses from these strains or genetically engineered
viruses could pinpoint what segment exactly carries de-
terminants for the competence phenotype to further in-
form risk analysis. The lower susceptibility of Cx.
quinquefasciatus, which is the most abundant domestic
vector and a highly anthropophilic species may explain
why human cases of RVFV are still rare in Senegal. Only
the strain belonging to the East African lineage
(SH172805) was transmitted, suggesting that this lineage
is more infectious for mosquito vectors than the West
African lineage in agreement with the fact than more
RVFV outbreaks were observed in East Africa compared
to West Africa.
Considering that Ae. vexans, Cx. poicilipes and Cx.
quinquefasciatus exhibited a minimum EIP of 10, 15 and
20 days, respectively and given their estimated survival
rates obtained from previous studies [64, 65], the infect-
ive life expectancy was estimated at between (0.91)10 to
(0.96)10 for Ae. vexans, between (0.70)15 to (0.79)15 for
Cx. poicilipes, and between (0.871)20 and (0.883)20 for
Cx. quinquefasciatus. This means that 38.9–66.4 % of
Ae. vexans, but only 0.5–2.9 % of Cx. poicilipes and
6.31–8.3 % of Cx. quinquefasciatus populations would
be expected to survive long enough for transmission to
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occur.ConclusionOur findings revealed that all the spe-
cies tested were competent for RVFV with a significant
more important role of Ae. vexans compared to Cx. poi-
cilipes or Cx. quinquefasciatus and a highest potential of
the East African lineage to be transmitted.
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